ロード中...
Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib
The overall survival for patients with advanced hepatocellular carcinoma (HCC) is still limited. Although the multi-kinase inhibitor sorafenib has recently been approved for this disease, response rates are still low and patients often face dose-limiting toxicities which lead to a reduction in progn...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The WJG Press and Baishideng
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2909561/ https://ncbi.nlm.nih.gov/pubmed/20653070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v16.i28.3592 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|